- What it is
- An acute neurological emergency caused by thiamine (vitamin B1) deficiency. Alcohol dependence is a common cause, but Wernicke’s can occur while a person is still drinking and is not limited to withdrawal.
- Mental-state relevance
- Confusion, memory disturbance, reduced attention or altered behaviour may be prominent. The familiar triad is often incomplete: current UK guidance highlights mental-status change alongside poor nutrition, ataxia or any eye-movement abnormality.
- Physical clues
- Unsteady gait or poor coordination, nystagmus, ophthalmoplegia or other abnormal eye movements, malnutrition, recent weight loss, persistent vomiting and peripheral neuropathy can add to the picture.
- Blood context
- There is no timely routine blood result that confirms or excludes Wernicke’s. A thiamine result must not delay presumptive treatment. Magnesium is particularly relevant because deficiency can prevent thiamine working properly. Other bloods may identify coexisting metabolic, nutritional, hepatic or infective contributors rather than prove Wernicke’s.
- Treatment context
- Suspected or established Wernicke’s is treated in hospital with urgent parenteral thiamine; current UK guidance prefers intravenous treatment, followed by oral thiamine, with magnesium reviewed and corrected when low. Mental-health liaison or psychiatry may identify the concern and coordinate with the treating team; the acute hospital policy supplies the exact product, dose, duration and clinical owner.
- Pabrinex
- Pabrinex is the familiar hospital name for Vitamin B&C Intravenous High Potency. It contains thiamine together with other B vitamins and vitamin C, and is indicated for rapid therapy of severe water-soluble vitamin depletion, particularly where thiamine depletion can lead to Wernicke’s encephalopathy.
Alcohol withdrawal syndrome
Alcohol withdrawal syndrome follows cessation of, or a substantial reduction in, prolonged heavy alcohol use.
Current UK guidance says symptoms generally begin within 6–24 hours of stopping and can last around a week. Older NICE evidence places many minor symptoms early, seizures mainly in the first 12–48 hours, and delirium tremens commonly around 48–72 hours. These are ordinary patterns, not an individual timetable.
Common features
- Tremor
- Sweating, palpitations and autonomic activation
- Anxiety, agitation, irritability and disturbed sleep
- Nausea, retching or vomiting
- Headache
More complicated presentation
- Tactile, auditory or visual disturbance
- New disorientation, confusion or altered arousal
- Seizure—even without a very high preceding score
- Delirium with marked tremor, agitation and autonomic disturbance
- An atypical course or physical deterioration
Medication treatment. Chlordiazepoxide is the benzodiazepine used locally in Blackpool. Current UK guidance identifies both chlordiazepoxide and diazepam as the benzodiazepines most commonly used for medically assisted alcohol withdrawal. The setting and current local protocol determine the choice, regimen and clinical responsibilities.
Sources: DHSC — Alcohol care in acute hospitals; DHSC — Pharmacological interventions.
CIWA-Ar: what the number represents
CIWA-Ar means Clinical Institute Withdrawal Assessment for Alcohol, revised. It is a 10-domain measure of current withdrawal severity.
CIWA-Ar covers nausea/vomiting, tremor, sweating, anxiety, agitation, tactile, auditory and visual disturbance, headache/head fullness, and orientation/clouding of sensorium.
How it is scored
- Nine domains are rated from 0 to 7.
- Orientation and clouding of sensorium are rated from 0 to 4.
- Each rating uses descriptive anchors running from no feature present to progressively more marked symptoms.
- The ten ratings are added to give a total from 0 to 67.
- Some ratings use the person’s account; others combine questioning with direct observation.
Its limits
- It does not diagnose withdrawal or explain a symptom.
- There is no universal medication threshold attached to every setting.
- Acute illness, delirium, communication difficulty and medication effects can distort the score.
Evidence in context. The 1989 revision used pooled data from 137 people in a specialist teaching-hospital setting. A later study of 479 acutely ill or injured hospital patients did not support reliability or validity in those populations.
Sources: Sullivan et al., 1989 — CIWA-Ar development; Higgins et al., 2019 — psychometric analysis in acutely ill and injured hospital patients; DHSC — assessment and treatment planning.
Wernicke’s encephalopathy — thiamine deficiency
Sources: DHSC — alcohol-related brain damage and Wernicke’s encephalopathy; emc — Pabrinex/Vitamin B&C Intravenous High Potency SmPC.
Hepatic encephalopathy — liver-related brain dysfunction
- What it is
- A neuropsychiatric complication of significant liver dysfunction or portosystemic shunting. It ranges from subtle loss of concentration and executive function to overt disorientation, stupor or coma.
- Mental-state relevance
- Sleep–wake reversal, reduced attention, short-term memory difficulty, lethargy, behaviour or personality change, confusion and fluctuating engagement may resemble depression, intoxication, withdrawal or another delirium.
- Physical clues
- Slurred speech, ataxia and asterixis may appear in overt hepatic encephalopathy. Asterixis is the irregular “flapping” produced by brief loss of sustained posture when the arms and hands are held out. It is not a classic Wernicke sign and is not unique to liver disease.
- Blood context
- Bilirubin, albumin, INR and platelet count contribute to the liver picture; electrolytes and evidence of infection may reveal precipitants. Ordinary liver blood tests can be normal even in cirrhosis. Ammonia is not routinely required: a normal value makes hepatic encephalopathy less likely, while a raised value is not a stand-alone diagnosis or severity score.
- Treatment context
- This is a medical or liver pathway. Treatment addresses the precipitating cause; British guidance identifies lactulose as first-line therapy and rifaximin as second-line for recurrent overt episodes. Sedating withdrawal medication may accumulate when liver function is compromised, so the medical context remains important.
Source: British Society of Gastroenterology — hepatic encephalopathy guidance.
Metabolic encephalopathy — systemic disturbance affecting the brain
- What it is
- An umbrella description rather than one disease. Brain function is disturbed by a wider physiological problem such as abnormal glucose or electrolytes, renal failure, hypoxia, infection, medication or another toxin.
- Mental-state relevance
- Acute or fluctuating confusion, poor attention, altered arousal, agitation, withdrawal, unusual behaviour or perceptual disturbance can all appear psychiatric at first glance. More than one physical cause may be active.
- Physical clues
- The surrounding presentation may include dehydration, vomiting, fever, abnormal oxygenation, reduced urine output, tremor, myoclonus, asterixis or changing consciousness. Asterixis can occur in several toxic or metabolic states, not only hepatic encephalopathy.
- Blood and physiology
- Glucose; sodium and other electrolytes; renal function; calcium, magnesium and phosphate; liver function; inflammatory markers; and, where relevant, oxygen and carbon-dioxide status may expose a physiological contributor. The pattern, severity, trend and whole presentation carry more meaning than one isolated result.
- Treatment context
- There is no single metabolic-encephalopathy treatment. The medical pathway identifies and corrects the underlying physiological disturbance or combination of disturbances.
Sources: NICE CG103 — delirium and physical contributors; NCBI Bookshelf — asterixis.
Alcohol, nutrition and mental state
This section concerns deficiency or depletion of the nutrients listed below. It is not describing raised levels.
| Nutrient | What deficiency or depletion may affect | Mental-health relevance |
|---|---|---|
| Thiamine (vitamin B1) | Essential to normal brain energy metabolism. Deficiency has the established relationship with Wernicke’s encephalopathy and alcohol-related brain damage. | Confusion, memory disturbance, ataxia and abnormal eye movements may be incomplete or mixed with intoxication, withdrawal or delirium. A blood result is not a reason to delay treatment when Wernicke’s is suspected. |
| Vitamin B12 | Supports blood-cell production and neurological function. Deficiency can occur without anaemia or macrocytosis. | Difficulty concentrating, short-term memory loss, depression, anxiety or psychosis may occur alongside neuropathy, sensory change, poor balance or impaired gait. These features are associations, not proof that B12 explains the presentation. |
| Folate | Supports blood-cell production and is often considered with B12 when macrocytosis, anaemia or poor nutrition is present. | Fatigue, cognitive change and psychological symptoms can accompany deficiency, but they are non-specific and may have several concurrent explanations. |
| Magnesium and phosphate | Deficiency may accompany malnutrition, vomiting, alcohol dependence or refeeding risk. Magnesium is needed for thiamine activation. | Deficiency can contribute to weakness, tremor, altered cognition, seizures or cardiac instability and may complicate the apparent withdrawal picture. |
Long-term harmful alcohol use can coexist with several nutritional deficiencies. Thiamine is the nutrient with the specific established link to Wernicke’s; B12, folate and electrolytes supply additional context rather than an automatic explanation.
Sources: DHSC — alcohol-related brain damage and thiamine; NICE NG239 — vitamin B12 deficiency; NHS — vitamin B12 or folate deficiency.
Overlap across the liaison presentation
| Presentation | What may fit | What keeps the picture open |
|---|---|---|
| Intoxication | Recent alcohol, disinhibition, dysarthria, ataxia, sedation or emotional lability. | Withdrawal can occur after a substantial reduction while alcohol remains present; a positive alcohol level neither proves nor excludes withdrawal. |
| Withdrawal | Time-linked reduction; tremor, sweating, anxiety/agitation, nausea, insomnia, perceptual change. | These features are non-specific and may coexist with physical illness or encephalopathy. |
| Delirium or encephalopathy | Acute or fluctuating attention, awareness, orientation or arousal. | Withdrawal, infection, hypoxia, metabolic disturbance, head injury, hepatic encephalopathy, Wernicke’s, medicines and other substances can act alone or together. |
| Primary mental illness | Anxiety, agitation, insomnia, mood or psychotic symptoms may resemble withdrawal. | A psychiatric history does not explain new autonomic signs, altered consciousness or fluctuating attention. Co-occurrence remains possible. |
| Medication or substance effects | Sedation, ataxia, dysarthria, confusion, agitation or tremor. | Prescribed, administered, non-prescribed and recently stopped substances may mask or reproduce withdrawal items. |
Sources: DHSC — alcohol care in acute hospitals; NICE CG103 — delirium and physical contributors; ASAM — alcohol withdrawal management.
Commonly assessed features
- Last drink, recent reduction and usual alcohol pattern.
- Previous withdrawal seizure, delirium tremens or complicated withdrawal.
- Observation trend, consciousness, attention and orientation.
- Vomiting, intake, weight loss, malnutrition or refeeding context.
- Eye movements, gait, coordination, tremor and asterixis.
- Liver disease, infection, injury, hypoxia and metabolic disturbance.
- Other substances and recently administered or prescribed medicines.
- A withdrawal score that conflicts with the presentation or cannot be completed reliably.
Sources: DHSC — alcohol care in acute hospitals; NICE CG103 — delirium assessment context.
Principal sources
- DHSC: Alcohol care in acute hospitals — current UK withdrawal, Wernicke, liver and nutritional guidance.
- DHSC: Pharmacological interventions — UK benzodiazepine and thiamine context.
- DHSC: People with alcohol-related brain damage — Wernicke recognition and urgency.
- NICE CG100 recommendations — withdrawal tools and parenteral thiamine.
- British Society of Gastroenterology guidance — hepatic encephalopathy, asterixis, ammonia and treatment context.
- NICE CG103 — delirium and physical contributors.
- NICE NG239 — B12 neurological, cognitive and mental-health associations.
- Sullivan et al., 1989 and Higgins et al., 2019 — CIWA-Ar development and acute-hospital limitations.
- emc: Pabrinex/Vitamin B&C Intravenous High Potency SmPC — current product identity, contents and indication.
Sources checked 1 August 2026. Exact local scoring and treatment actions remain governed by the current local policy.